Disease 12th Edition Hot!: S Gastrointestinal And Liver

: A dedicated new chapter on the gastrointestinal and hepatic manifestations of coronavirus infections. Immunotherapy Complications

The latest edition of Sleisenger and Fordtran's boasts significant updates, including:

Updated chapters on the genetic basis of liver diseases, advancements in the management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and the latest in antiviral therapies for hepatitis [Source 1, Source 2]. s gastrointestinal and liver disease 12th edition

The 12th edition retains the beloved "Sleisenger" format but adds modern learning tools:

The 12th edition of Sleisenger and Fordtran's Gastrointestinal and Liver Disease is not simply an updated textbook; it is a comprehensive, modern, and practical guide that arrives at a pivotal time. With a new editorial team at the helm, it brilliantly balances the wisdom of its storied past with the urgent needs of contemporary clinical practice. The addition of new chapters on COVID-19 manifestations, cancer immunotherapy side effects, and AI in endoscopy demonstrates a profound commitment to staying ahead of the curve. : A dedicated new chapter on the gastrointestinal

The 12th edition maintains a highly intuitive, multi-volume structure designed for rapid information retrieval and deep conceptual learning. The text is systematically divided into major sections that cover:

Cirrhosis, portal hypertension, and complications. Fatty Liver Disease: The rising epidemic of NASH and NAFLD. With a new editorial team at the helm,

Provides a structured, comprehensive curriculum required to master the specialty and excel in board examinations.

Functional GI disorders (IBS, functional dyspepsia) are no longer considered "diagnoses of exclusion." The new edition integrates the latest Rome IV criteria and dedicates entire chapters to the neuroscience of the gut-brain axis. You will find updated algorithms for managing refractory IBS, including the role of dietary interventions (low FODMAP), gut-directed hypnotherapy, and novel pharmacological agents like tenapanor and ibodutant.